Fig. 5

A schematic diagram of an integrative molecular approach for TOO identification for lung-specific CUP. Comprehensive genome profiling was first performed and subjected to a decision flow that yields five possible inferences, among which the inconclusive cases subsequently undergo DNA methylation analysis. Aberrant EGFR, ALK or ROS1 refers to clinically actionable EGFR mutations or deletions or ALK or ROS1 rearrangements detected in samples from both disease sites